Techno Drugs Ltd. (DSE:TECHNODRUG)
Bangladesh
· Delayed Price · Currency is BDT 27.80
-1.50 (-5.12%)
At close: Mar 8, 2026
Techno Drugs Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| Revenue | 3,150 | 3,376 | 3,613 | 2,733 | 5,029 |
| Revenue Growth (YoY) | 5.24% | -6.58% | 32.19% | -45.64% | - |
| Cost of Revenue | 1,786 | 1,919 | 2,098 | 1,579 | 3,224 |
| Gross Profit | 1,364 | 1,457 | 1,515 | 1,154 | 1,804 |
| Selling, General & Admin | 679.11 | 758.69 | 848.23 | 628.04 | 905.09 |
| Operating Expenses | 679.11 | 758.69 | 848.23 | 628.04 | 905.09 |
| Operating Income | 684.9 | 698.33 | 666.8 | 526 | 899.4 |
| Interest Expense | -422.44 | -411.48 | -305.93 | -263.87 | -256.61 |
| Interest & Investment Income | 1.85 | 1.85 | 2.55 | 2.62 | 11.97 |
| Currency Exchange Gain (Loss) | - | - | -0.19 | -0.01 | - |
| Other Non Operating Income (Expenses) | -2.51 | -1.86 | -3.64 | -5.69 | -3.74 |
| Pretax Income | 261.8 | 286.83 | 359.59 | 259.05 | 651.02 |
| Income Tax Expense | 56.26 | 54.81 | 78.99 | 63.55 | 171.24 |
| Net Income | 205.53 | 232.02 | 280.6 | 195.51 | 479.78 |
| Net Income to Common | 205.53 | 232.02 | 280.6 | 195.51 | 479.78 |
| Net Income Growth | -6.04% | -17.31% | 43.53% | -59.25% | - |
| Shares Outstanding (Basic) | 132 | 132 | 95 | 94 | 94 |
| Shares Outstanding (Diluted) | 132 | 132 | 95 | 94 | 94 |
| Shares Change (YoY) | 15.69% | 38.07% | 1.34% | - | - |
| EPS (Basic) | 1.56 | 1.76 | 2.94 | 2.08 | 5.10 |
| EPS (Diluted) | 1.56 | 1.76 | 2.94 | 2.08 | 5.10 |
| EPS Growth | -18.78% | -40.11% | 41.62% | -59.25% | - |
| Free Cash Flow | -141.96 | -479.52 | 83.64 | -416.28 | -1.52 |
| Free Cash Flow Per Share | -1.07 | -3.64 | 0.88 | -4.42 | -0.02 |
| Dividend Per Share | - | 1.000 | 1.200 | - | - |
| Dividend Growth | - | -16.67% | - | - | - |
| Gross Margin | 43.30% | 43.16% | 41.93% | 42.22% | 35.88% |
| Operating Margin | 21.74% | 20.69% | 18.45% | 19.24% | 17.89% |
| Profit Margin | 6.53% | 6.87% | 7.77% | 7.15% | 9.54% |
| Free Cash Flow Margin | -4.51% | -14.21% | 2.31% | -15.23% | -0.03% |
| EBITDA | 1,055 | 1,053 | 990.74 | 817.36 | 1,151 |
| EBITDA Margin | 33.48% | 31.19% | 27.42% | 29.90% | 22.89% |
| D&A For EBITDA | 369.61 | 354.38 | 323.94 | 291.35 | 251.54 |
| EBIT | 684.9 | 698.33 | 666.8 | 526 | 899.4 |
| EBIT Margin | 21.74% | 20.69% | 18.45% | 19.24% | 17.89% |
| Effective Tax Rate | 21.49% | 19.11% | 21.97% | 24.53% | 26.30% |
| Advertising Expenses | - | 1.37 | 0.76 | 0.26 | 0.59 |
Source: S&P Capital IQ. Standard template. Financial Sources.